Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

AIDS

Volumn 16, Issue 7, 2002, Pages 1009-1017

  Prado, Julia G ^a   Wrin, Terri ^a   Beauchaine, Jeff ^a   Ruiz, Lidia ^a   Petropoulos, Christos J ^a   Frost, Simon D W ^a   Clotet, Bonaventura ^a   D'Aquila, Richard T ^a   Martinez Picado, Javier ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Amprenavir; HIV 1 drug resistance; Lopinavir; Protease inhibitors; Replication capacity; Viral fitness

Indexed keywords

AMPRENAVIR; GAG PROTEIN; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CROSS RESISTANCE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

CARBAMATES; CODON; DRUG RESISTANCE, MULTIPLE, VIRAL; GENES, GAG; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MUTATION; PHENOTYPE; PYRIMIDINONES; RECOMBINATION, GENETIC; SULFONAMIDES; VIRUS REPLICATION;

EID: 0037012979     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205030-00007     Document Type: Article

References (30)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
2. Protease inhibitors, resistance, cross-resistance, fitness and the choice of initial and salvage therapies
3. Resistance to human immunodeficiency virus type 1 protease inhibitors
4. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents
5. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
6. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
7. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
8. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
9. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing
10. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
11. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeflciency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group
12. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
13. Virologic and immunologic consequences of discontinuing combination antiretrovlral-drug therapy in HIV-infected patients with detectable viremia
14. Drug resistance is associated with impaired protease and reverse transcriptase function and reduced replication capacity: Characterization of recombinant viruses derived from 200 HIV-1 infected patients
15. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants
16. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSense HIV
17. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors
18. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients
19. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
20. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects. AIDS Clinical Trials Group protocol 373
21. Amprenavir resistant mutants show reduced viral fitness: Correlation of protease mutations, cleavage site mutations, enzyme kinetics, viral polyprotein processing and viral growth kinetics
22. Treatment interruptions in HIV-1 infected patients with treatment failure: Virological and immunological effects
23. HIV-1 viral background plays a major role in development of resistance to protease inhibitors
24. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
25. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants
26. Characterization of HIV-1 variants with increased resistance to a C2-symmetric protease inhibitor
27. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
28. Second locus involved in HIV-1 resistance to protease inhibitors
29. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
30. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays